Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase I/Ib Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced or Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

A Multicenter Phase I/Ib Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; WTX-124 (Primary)
  • Indications Carcinoma; Gastric cancer; Malignant melanoma; Oesophageal cancer; Renal cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Werewolf Therapeutics

    • Most Recent Events

    • 04 Jun 2024 Results ( As of January 29, 2024, n=32) assessing safety and efficacy of WTX-124 in patients with locally advanced or metastatic solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 01 Jun 2024 According to a Werewolf Therapeutics Media Release, company will host a webcast at 8:00 am ET on Monday, June 3, 2024, to review this study results presented at ASCO. W
    • 01 Jun 2024 According to a Werewolf Therapeutics Media Release, data from this trial presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, and in a webcast on June 3, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top